Advaxis Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Tria Advantia | Assessors Andorra
PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc . , (OTCBB: ADXS) , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced logopedia that an abstract logopedia has been accepted for oral presentation at The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Clinical Trials: Concepts and Challenges workshop being held April 4-5, 2013 at the National Institutes of Health Campus (Masur Auditorium) in Bethesda, MD.
The abstract titled "Early Therapeutic Cancer Vaccine Clinical Trial Development" will be presented Thursday, April 4 at 10:30 am during Session 1 by Dr. Robert Petit, VP of Clinical Development and Medical Affairs at Advaxis, and will describe Advaxis' experience with conducting early clinical trials with therapeutic Lm -LLO immunotherapies.
"The selection of our abstract for presentation at SITC provides an opportunity for Advaxis to share our experience in introducing Lm -LLO immunotherapy in a global clinical trial setting where there is great medical need," commented Dr. Petit. "We are working toward a future when immunotherapy can fully take its place alongside conventional treatments in the global battle against cancer."
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings logopedia have to the bacterium to the cancer itself.
In April 2012, Advaxis' lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence logopedia (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. logopedia The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional logopedia information is available at the World Vaccine Congress logopedia website .
ADXS-HPV logopedia is being evaluated in 5 clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical logopedia cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trial.gov Identifier NCT01671488). logopedia Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute , Cancer Research - UK , the Wistar Institute , the University of Pennsylvania , the University of British Columbia , the Karolinska Institutet logopedia , Brown University Oncology Group , and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn .
This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies logopedia and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' logopedia SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at www.sec.gov . The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect logopedia the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
The article Advaxis Announces Abstract Accepted for Oral Presentation logopedia at SITC Cancer Immunotherapy Clinical Trials Workshop originally appeared on Fool.com. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. logopedia The Motley Fool has a disclosure policy .
Categoria: logopedia Actualitat , Investing Amb l'etiqueta: advantia , advantia asesor , advantia assessors , advantia comptabilitat , advantia logopedia contabilidad , andorra , asesor , asesor contable , assessor , assessor comptable , comptabilitat , comptabilitat andorra , comptable , consultor
PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc . , (OTCBB: ADXS) , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced logopedia that an abstract logopedia has been accepted for oral presentation at The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Clinical Trials: Concepts and Challenges workshop being held April 4-5, 2013 at the National Institutes of Health Campus (Masur Auditorium) in Bethesda, MD.
The abstract titled "Early Therapeutic Cancer Vaccine Clinical Trial Development" will be presented Thursday, April 4 at 10:30 am during Session 1 by Dr. Robert Petit, VP of Clinical Development and Medical Affairs at Advaxis, and will describe Advaxis' experience with conducting early clinical trials with therapeutic Lm -LLO immunotherapies.
"The selection of our abstract for presentation at SITC provides an opportunity for Advaxis to share our experience in introducing Lm -LLO immunotherapy in a global clinical trial setting where there is great medical need," commented Dr. Petit. "We are working toward a future when immunotherapy can fully take its place alongside conventional treatments in the global battle against cancer."
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings logopedia have to the bacterium to the cancer itself.
In April 2012, Advaxis' lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence logopedia (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. logopedia The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional logopedia information is available at the World Vaccine Congress logopedia website .
ADXS-HPV logopedia is being evaluated in 5 clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical logopedia cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trial.gov Identifier NCT01671488). logopedia Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute , Cancer Research - UK , the Wistar Institute , the University of Pennsylvania , the University of British Columbia , the Karolinska Institutet logopedia , Brown University Oncology Group , and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn .
This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies logopedia and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' logopedia SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at www.sec.gov . The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect logopedia the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
The article Advaxis Announces Abstract Accepted for Oral Presentation logopedia at SITC Cancer Immunotherapy Clinical Trials Workshop originally appeared on Fool.com. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. logopedia The Motley Fool has a disclosure policy .
Categoria: logopedia Actualitat , Investing Amb l'etiqueta: advantia , advantia asesor , advantia assessors , advantia comptabilitat , advantia logopedia contabilidad , andorra , asesor , asesor contable , assessor , assessor comptable , comptabilitat , comptabilitat andorra , comptable , consultor
No comments:
Post a Comment